Whether BRCA1 or BRCA2 mutation is more dangerous in breast cancer cases based on the given study. Introduction: Cancer is a disease in which there is an abnormal growth of cells due to unlimited cell division. It is a genetic disease which is characterized by the changes in the genes due to certain mutations. The abnormal cells are called tumor or cancer cells. Tumor suppressor genes inhibit the growth and cell division of the abnormal cells. When inactivated by mutations, these genes lose their inhibitory properties causing an increase in the cell division leading to cancer.

Question

Describe error prone polymerases and the process of translesion synthesis (TLS). In regards to tumor biology, what is the mutator phenotype hypothesis? What are some ways in which error-prone polymerases could be targeted for potential anti-cancer treatments?

Answer 1

Question

Chapter 16, Problem 3ITD

Summary Introduction

To review:

Whether BRCA1or BRCA2 mutation is more dangerous in breast cancer cases based on the given study.

Introduction:

Cancer is a disease in which there is an abnormal growth of cells due to unlimited cell division. It is a genetic disease which is characterized by the changes in the genes due to certain mutations. The abnormal cells are called tumor or cancer cells. Tumor suppressor genes inhibit the growth and cell division of the abnormal cells. When inactivated by mutations, these genes lose their inhibitory properties causing an increase in the cell division leading to cancer.

Expert Solution & Answer

Trending nowThis is a popular solution!

See solution

Check out sample textbook solution

Students have asked these similar questions

Describe error prone polymerases and the process of translesion synthesis (TLS). In regards to tumor biology, what is the mutator phenotype hypothesis? What are some ways in which error-prone polymerases could be targeted for potential anti-cancer treatments?

In Demircioglu et al (2019), the authors found that promoter switching for the ERBB2 gene was often associated with mutations in other known oncogenes and tumor suppresor genes. However, they argued that promoter switching may be correlated with cancer development and progression regardless of additional mutations. What evidence did they have to support this idea ? O They found that patients who had ERBB2 promoter switching but no other mutations in known oncogenes (OG) and tumor suppressor genes (TSG) carried many other mutations in genes that may have contributed to cancer progression and had not been identified as OG or TSG yet. O They saw that patients that showed promoter switching but did not have any other identifiable mutations had poorer prognosis than patients without promoter switching This was actually a discussion point; the authors did not have any experimental evidence to support their claim. O They treated all patients that showed promoter switching with the same drug…

The MET oncogene is a growth factor receptor that is altered in many forms of cancer including lung and colon carcinomas as well as several forms of melanoma. One assay for characterizing the gene composition of tumor cells is Fluorescence in situ Hybridization (FISH) in which a fluorescently labeled DNA is used to show the presence of and level (i.e. number copies) of a gene inside cells. The experiment below is a FISH assay of two different tumor samples (Patient D and Patient E) using a MET gene probe labeled with a green fluorescent probe. The figure on the right presents the survival data from diagnosis of cancer patients with FISH data similar to Patient D or E. Based on this data, what has happened to the MET gene in Patient D population that has made their cancer more severe and reduced survival time (Limit 4-5 sentences). D Survival rate (%) 100 0 0 100 200 Time (days) 300 E